Solares S, Leon J, Garcia-Gutierrez L
Cancers (Basel). 2025; 16(24.
PMID: 39766110
PMC: 11674381.
DOI: 10.3390/cancers16244212.
Corallo S, Lasagna A, Filippi B, Alaimo D, Tortorella A, Serra F
Pathogens. 2024; 13(9).
PMID: 39338919
PMC: 11435077.
DOI: 10.3390/pathogens13090728.
Wong K, Hui K, Lam K, Kwong D, Lung M, Yang W
PLoS Pathog. 2024; 20(5):e1012263.
PMID: 38805547
PMC: 11161099.
DOI: 10.1371/journal.ppat.1012263.
Moreddu R, Boschi A, dAmora M, Hubarevich A, Dipalo M, De Angelis F
Nano Lett. 2023; 23(8):3217-3223.
PMID: 37019439
PMC: 10141418.
DOI: 10.1021/acs.nanolett.2c05053.
Ward B, Schaal D, Nkadi E, Scott R
Viruses. 2022; 14(12).
PMID: 36560704
PMC: 9783324.
DOI: 10.3390/v14122700.
Epstein-Barr virus: Biology and clinical disease.
Damania B, Kenney S, Raab-Traub N
Cell. 2022; 185(20):3652-3670.
PMID: 36113467
PMC: 9529843.
DOI: 10.1016/j.cell.2022.08.026.
Impact of Tumour Epstein-Barr Virus Status on Clinical Outcome in Patients with Classical Hodgkin Lymphoma (cHL): A Review of the Literature and Analysis of a Clinical Trial Cohort of Children with cHL.
Nohtani M, Vrzalikova K, Ibrahim M, Powell J, Fennell E, Morgan S
Cancers (Basel). 2022; 14(17).
PMID: 36077832
PMC: 9454639.
DOI: 10.3390/cancers14174297.
The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein-Barr Virus Infection.
Ohashi A, Uemura Y, Yoshimori M, Wada N, Imadome K, Yudo K
Front Microbiol. 2022; 13:874998.
PMID: 35464987
PMC: 9019545.
DOI: 10.3389/fmicb.2022.874998.
Oncogenic Viruses as Entropic Drivers of Cancer Evolution.
Tempera I, Lieberman P
Front Virol. 2022; 1.
PMID: 35141704
PMC: 8822580.
DOI: 10.3389/fviro.2021.753366.
Virus-Driven Carcinogenesis.
Hatano Y, Ideta T, Hirata A, Hatano K, Tomita H, Okada H
Cancers (Basel). 2021; 13(11).
PMID: 34071792
PMC: 8198641.
DOI: 10.3390/cancers13112625.
Utilization of Host Cell Chromosome Conformation by Viral Pathogens: Knowing When to Hold and When to Fold.
Majumder K, Morales A
Front Immunol. 2021; 12:633762.
PMID: 33841414
PMC: 8027251.
DOI: 10.3389/fimmu.2021.633762.
The Role of NK Cells in EBV Infection and EBV-Associated NPC.
Png Y, Yang A, Lee M, Chua M, Lim C
Viruses. 2021; 13(2).
PMID: 33671917
PMC: 7918975.
DOI: 10.3390/v13020300.
Is EBV Associated with Breast Cancer in Specific Geographic Locations?.
Sinclair A, Moalwi M, Amoaten T
Cancers (Basel). 2021; 13(4).
PMID: 33669217
PMC: 7919813.
DOI: 10.3390/cancers13040819.
Ephrin receptor A2, the epithelial receptor for Epstein-Barr virus entry, is not available for efficient infection in human gastric organoids.
Wallaschek N, Reuter S, Silkenat S, Wolf K, Niklas C, Kayisoglu O
PLoS Pathog. 2021; 17(2):e1009210.
PMID: 33596248
PMC: 7935236.
DOI: 10.1371/journal.ppat.1009210.
Burkitt Lymphomas Evolve to Escape Dependencies on Epstein-Barr Virus.
Hutcheson R, Chakravorty A, Sugden B
Front Cell Infect Microbiol. 2021; 10:606412.
PMID: 33505922
PMC: 7829347.
DOI: 10.3389/fcimb.2020.606412.
Epstein-Barr Virus Mediated Signaling in Nasopharyngeal Carcinoma Carcinogenesis.
Richardo T, Prattapong P, Ngernsombat C, Wisetyaningsih N, Iizasa H, Yoshiyama H
Cancers (Basel). 2020; 12(9).
PMID: 32872147
PMC: 7565514.
DOI: 10.3390/cancers12092441.
Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification.
Yonese I, Sakashita C, Imadome K, Kobayashi T, Yamamoto M, Sawada A
Blood Adv. 2020; 4(13):2918-2926.
PMID: 32598475
PMC: 7362364.
DOI: 10.1182/bloodadvances.2020001451.
Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma.
Hau P, Lung H, Wu M, Tsang C, Wong K, Mak N
Front Oncol. 2020; 10:600.
PMID: 32528868
PMC: 7247807.
DOI: 10.3389/fonc.2020.00600.
Epstein-Barr Virus Infection of Oral Squamous Cells.
Heawchaiyaphum C, Iizasa H, Ekalaksananan T, Burassakarn A, Kiyono T, Kanehiro Y
Microorganisms. 2020; 8(3).
PMID: 32188127
PMC: 7144007.
DOI: 10.3390/microorganisms8030419.
Epstein-Barr Virus-Encoded Products Promote Circulating Tumor Cell Generation: A Novel Mechanism of Nasopharyngeal Carcinoma Metastasis.
Yang Z, Wang J, Zhang Z, Tang F
Onco Targets Ther. 2020; 12:11793-11804.
PMID: 32099385
PMC: 6997419.
DOI: 10.2147/OTT.S235948.